131-I radioiodine therapy for hyperthyroidism in patients with Graves' disease, uninodular goitre and multinodular goitre.
We studied 201 consecutive patients who received a relatively fixed dose of radioiodine for the treatment of hyperthyroidism between the years 1981-6. Patients with Graves' disease (170) were initially treated with a mean (SE) dose of 369 (10) MBq 131-I with a remission rate of 94% at 6 months and a cumulative relapse rate of 12% at one year and 21% at 5 years. The cumulative incidence of hypothyroidism was 26% at 3 months, 55% at 6 months, 61% at 1 year and 66% at 5 years. Patients with a uninodular goitre (10) were initially treated with a mean (SE) dose of 438 (85) MBq 131-I with a remission rate of 100% at 6 months, without relapse at 1 year but relapsing in 17% at 5 years. The cumulative incidence of hypothyroidism was 26% at 3 months, 30% at 6 months, 40% at 1 year and 40% at 5 years. Patients with a multinodular goitre (21) were initially treated with a mean (SE) dose of 613 (77) MBq 131-I with a remission rate of 79% at 6 months and a cumulative relapse rate of 26% at 1 year and 39% at 5 years. The cumulative incidence of hypothyroidism was 5% at 3 months, 14% at 6 months, 24% at 1 year and 24% at 5 years.
Danaci
M
M
Department of Medicine, Western General Hospital, Edinburgh, Scotland.
Feek
C M
CM
Notghi
A
A
Merrick
M V
MV
Padfield
P L
PL
Edwards
C R
CR
D000368:Aged; D005260:Female; D006044:Goiter, Nodular / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D006111:Graves Disease / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D006801:Humans; D006980:Hyperthyroidism / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011336:Probability; D011877:Radionuclide Imaging; D012189:Retrospective Studies
D007457:Iodine Radioisotopes